Gretchen C Edwards1, Adriana C Gamboa2, Michael P Feng1, Roberta L Muldoon3, Michael B Hopkins3, Sherif Abdel-Misih4, Glen C Balch5, Jennifer Holder-Murray6, Maryam Mohammed6, Scott E Regenbogen7, Matthew L Silviera8, Alexander T Hawkins9. 1. Department of Surgery, Vanderbilt University Medical Center, Nashville, TN. 2. Division of Surgical Oncology, Department of Surgery, Emory University School of Medicine, Atlanta, GA. 3. Division of Colon and Rectal Surgery, Department of Surgery, Vanderbilt University Medical Center, Nashville, TN. 4. Division of Surgical Oncology, Department of Surgery, Stony Brook University Hospital, Stony Brook, NY. 5. Division of Colorectal Surgery, Department of Surgery, Emory University School of Medicine, Atlanta, GA. 6. Division of Colon and Rectal Surgery, Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA. 7. Division of Colorectal Surgery, Department of Surgery, University of Michigan, Ann Arbor, MI. 8. Division of Colon and Rectal Surgery, Department of Surgery, Washington University, St Louis, MO. 9. Division of Colon and Rectal Surgery, Department of Surgery, Vanderbilt University Medical Center, Nashville, TN. Electronic address: alex.hawkins@vumc.org.
Abstract
BACKGROUND: National guidelines, including the National Accreditation Program for Rectal Cancer, recommend initiation of rectal cancer treatment within 60 days of diagnosis; however, the effect of timely treatment initiation on oncologic outcomes is unclear. The purpose of this study was to evaluate the impact on oncologic outcomes of initiation of rectal cancer treatment within 60 days of diagnosis. METHODS: This was a retrospective review of stage II/III rectal cancer patients performed using the United States Rectal Cancer Consortium, a collaboration of 6 academic medical centers. Patients with clinical stage II/III rectal cancer who underwent radical resection between January 1, 2010 and December 31, 2018 were included. The primary exposure was treatment initiation, defined as either resection or initiation of chemotherapy or chemoradiotherapy, within 60 days of diagnosis. The primary outcome was disease recurrence, and the secondary outcome was all-cause mortality. RESULTS: A total of 1,031 patients meeting inclusion criteria were included in the analysis. Treatment was initiated within 60 days of diagnosis in 830 patients (80.5%) and after 60 days in 201 patients (20.3%). In multivariable logistic regression, older age, non-White race, and residence greater than 100 miles from the treatment center were significantly associated with delay in treatment beyond 60 days. In survival analysis, 167 patients (16.2%) experienced recurrent disease, and 127 patients (12.3%) died of any cause. In an adjusted model accounting for pathologic staging, treatment sequence, distance to care, age, comorbidities, treatment center, and receipt of adjuvant chemotherapy, neither progression-free survival nor all-cause mortality was significantly associated with timely initiation of therapy with hazard ratios of 1.09 (0.70, 1.69) and 1.03 (0.63, 1.66), respectively. CONCLUSION: This study found no difference in oncologic outcomes with initiation of treatment beyond 60 days.
BACKGROUND: National guidelines, including the National Accreditation Program for Rectal Cancer, recommend initiation of rectal cancer treatment within 60 days of diagnosis; however, the effect of timely treatment initiation on oncologic outcomes is unclear. The purpose of this study was to evaluate the impact on oncologic outcomes of initiation of rectal cancer treatment within 60 days of diagnosis. METHODS: This was a retrospective review of stage II/III rectal cancer patients performed using the United States Rectal Cancer Consortium, a collaboration of 6 academic medical centers. Patients with clinical stage II/III rectal cancer who underwent radical resection between January 1, 2010 and December 31, 2018 were included. The primary exposure was treatment initiation, defined as either resection or initiation of chemotherapy or chemoradiotherapy, within 60 days of diagnosis. The primary outcome was disease recurrence, and the secondary outcome was all-cause mortality. RESULTS: A total of 1,031 patients meeting inclusion criteria were included in the analysis. Treatment was initiated within 60 days of diagnosis in 830 patients (80.5%) and after 60 days in 201 patients (20.3%). In multivariable logistic regression, older age, non-White race, and residence greater than 100 miles from the treatment center were significantly associated with delay in treatment beyond 60 days. In survival analysis, 167 patients (16.2%) experienced recurrent disease, and 127 patients (12.3%) died of any cause. In an adjusted model accounting for pathologic staging, treatment sequence, distance to care, age, comorbidities, treatment center, and receipt of adjuvant chemotherapy, neither progression-free survival nor all-cause mortality was significantly associated with timely initiation of therapy with hazard ratios of 1.09 (0.70, 1.69) and 1.03 (0.63, 1.66), respectively. CONCLUSION: This study found no difference in oncologic outcomes with initiation of treatment beyond 60 days.
Authors: Amanda R Kupstas; Tanya L Hoskin; Courtney N Day; Elizabeth B Habermann; Judy C Boughey Journal: Ann Surg Oncol Date: 2019-07-22 Impact factor: 5.344
Authors: Jeong-Heum Baek; Abdulhadi Alrubaie; Eduardo A Guzman; Sun Keun Choi; Casandra Anderson; Steven Mills; Joseph Carmichael; Andy Dagis; Dajun Qian; Joseph Kim; Julio Garcia-Aguilar; Michael J Stamos; Lisa Bening; Alessio Pigazzi Journal: Int J Colorectal Dis Date: 2012-07-29 Impact factor: 2.571
Authors: Harminder Singh; Emma Shu; Alain Demers; Charles N Bernstein; Jane Griffith; Katherine Fradette Journal: Can J Gastroenterol Date: 2012-12 Impact factor: 3.522
Authors: Zhaomin Xu; Adan Z Becerra; Carla F Justiniano; Courtney I Boodry; Christopher T Aquina; Alex A Swanger; Larissa K Temple; Fergal J Fleming Journal: Dis Colon Rectum Date: 2017-12 Impact factor: 4.585
Authors: Ryan P Merkow; Karl Y Bilimoria; Karen L Sherman; Martin D McCarter; Howard S Gordon; David J Bentrem Journal: J Oncol Pract Date: 2013-02-26 Impact factor: 3.840
Authors: Michael R Freund; Ilan Kent; Nir Horesh; Timothy Smith; Marcella Zamis; Ryan Meyer; Shlomo Yellinek; Steven D Wexner Journal: Surgery Date: 2022-02-17 Impact factor: 4.348